Clinical trials
Lupus or SLE clinical trials
Below are recruiting lupus or sle clinical trials, each written for real people, not researchers. We’re tracking 344 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07043153Recruiting
Predicting lupus disease activity with blood tests
This study looks at whether two blood markers (AGR and PNI) can help track how active lupus is. You may be eligible if you have lupus and are not pregnant or have other serious health conditions.
SohagAges 18 years+ - NCT06718283Recruiting
A study of blood tests in young people with lupus
This study looks at blood test results in children and teenagers with lupus to see if they relate to how active the disease is or if it has caused long-term damage. It may help doctors better understand the disease.
SohagAges Up to 18 years - NCT07302113Recruiting
Online thinking skills program for teens with lupus
This study tests a virtual (online) program to help teens with lupus improve thinking and daily life skills. It is designed for youth ages 13–18 with childhood-onset lupus.
Toronto, OntarioAges 13–18 - NCT07229742RecruitingPhase 2
Study of SHR-2173 for active lupus nephritis
This trial tests a new medicine called SHR-2173 for people with active lupus nephritis, a kidney inflammation caused by lupus. The goal is to see if it is safe and effective.
Nanjing, JiangsuAges 18–70 - NCT07017868Recruiting
Uric acid and other blood markers in lupus kidney disease
This study looks at whether certain substances in the blood, such as uric acid, homocysteine, and interleukin-17, are higher in people with lupus-related kidney disease compared to healthy individuals. It aims to find new ways to monitor or understand the condition better.
SohagAges 18 years+ - NCT06713187Recruiting
Interleukin-23 study in lupus and lung disease
This trial looks at a protein called interleukin-23 in people with lupus, especially those who also have lung inflammation (interstitial lung disease). The goal is to understand more about this protein's role and possibly find new ways to help.
SohagAges 18–60 - NCT05039619RecruitingPhase 2
Obinutuzumab trial for adolescents with active lupus kidney inflammation
This Phase 2 study tests obinutuzumab, a targeted antibody medicine, in teens with active lupus nephritis (inflammation in the kidney). It looks at whether it helps kidney disease and is safe, including how the body handles the drug.
Loma Linda, CaliforniaAges 5–17 - NCT07611214RecruitingPhase 4
LUPKYNIS Combined With Immune-Targeting Drugs for Lupus Kidney Disease
This study tests whether adding LUPKYNIS (a drug that protects the kidney) to one of three immune-system medications helps people with lupus nephritis (lupus affecting the kidneys). The goal is to reduce protein in urine and protect kidney function.
La Mesa, CaliforniaAges 18–75 - NCT07363590RecruitingPhase 1
Study of MK-1045 for lupus or rheumatoid arthritis
This study tests a new drug, MK-1045, for people with lupus or rheumatoid arthritis. It aims to see if the drug is safe and how it affects your condition.
Southport, QueenslandAges 18–75 - NCT07438496RecruitingPhase 3
Study of nipocalimab for moderate to severe lupus
This trial tests a new medicine, nipocalimab, for adults with moderate to severe lupus. It aims to see if the drug can help control lupus symptoms and reduce disease activity.
Beverly Hills, CaliforniaAges 18–75 - NCT06475742Enrolling by invitationPhase 3
Long-term safety of cenerimod in lupus patients
This study tests the long-term safety of a drug called cenerimod for people with lupus (SLE) who have already completed a 12-month study of the same drug. It helps researchers see if the medicine stays safe and tolerable over a longer period.
Aurora, ColoradoAges 18–75 - NCT07700940RecruitingPhase 4
Empagliflozin for kidney function in lupus nephritis
This trial tests if empagliflozin, a medicine used for diabetes, can help protect kidney function in people with active lupus nephritis. You may be eligible if you have a lupus kidney flare with significant protein in your urine.
Banī SuwayfAges 18–65 - NCT03001973Recruiting
Study of Chinese lupus kidney inflammation evidence
This trial is for people who have lupus nephritis, which means lupus affecting the kidneys. It aims to gather high-quality evidence that may help improve how this condition is understood and cared for.
Guangzhou, GuangdongAges 14 years+ - NCT03138941Recruiting
Checking if a lupus control definition fits Asia-Pacific patients
This study tests whether a specific lupus “low disease activity” target (called LLDAS) works the same way in people across the Asia-Pacific region. It may help doctors use clearer goals to track how well lupus is controlled.
Adelaide, South AustraliaAges 18 years+ - NCT03276923Recruiting
Pregnancy registry for women with autoimmune disease
This study is a pregnancy and health registry for women with autoimmune (immune system) conditions who are trying to become pregnant or are already pregnant. It helps researchers better understand pregnancy outcomes and health needs in autoimmune disease.
Durham, North CarolinaAges Any age - NCT04449991Recruiting
Repeat kidney biopsy in new lupus kidney disease
This study looks at whether doing a planned second kidney biopsy about 12 months later helps doctors understand and guide treatment for people with newly diagnosed lupus nephritis. You may be put on standard lupus-kidney medications, and the main “test” is the repeat biopsy timing.
StockholmAges 18 years+ - NCT05201469RecruitingPhase 2
VIB4920 for lupus kidney inflammation not responding well enough
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
La Jolla, CaliforniaAges 18 years+ - NCT05207358RecruitingPhase 4
Lower steroid use in active lupus kidney inflammation
This trial looks at whether people with proliferative lupus nephritis can use less steroid medicine while still controlling kidney inflammation. It may help reduce steroid side effects, while testing a carefully monitored treatment plan.
BucharestAges 18–80 - NCT05268289RecruitingPhase 2
Trial for lupus kidney inflammation using LNP023
This Phase 2 study tests whether LNP023 can improve outcomes and safety in people with active lupus nephritis (lupus-related kidney inflammation), class III or IV. It may help by targeting the ongoing immune activity that is damaging the kidneys.
Phoenix, ArizonaAges 18–100 - NCT05394922Recruiting
Study of sugar patterns in lupus anti-DNA antibodies
This study looks at the “sugar coating” on anti-DNA antibodies in people with lupus. The goal is to better understand these antibody patterns, which may help improve how lupus is studied or treated in the future.
MontpellierAges 18–80 - NCT05443516Recruiting
Blood and urine markers in active lupus kidney disease
This study looks at blood and urine markers that may show how active lupus kidney disease is and how it changes over time. It may help doctors better monitor people with active lupus-related kidney inflammation.
BrusselsAges 18–70 - NCT05538208RecruitingPhase 2
Children with lupus kidney inflammation using mycophenolate
This Phase 2 study tests how well the medicine mycophenolate mofetil (MMF) works for children and teens with lupus nephritis that is “proliferative” (a specific biopsy type). You may qualify if your kidney biopsy and current treatment match the study’s targets and you can follow frequent visits and testing.
San Francisco, CaliforniaAges 8–20 - NCT05559671RecruitingPhase 4
Shingles vaccine safety study for people with lupus
This Phase 4 study checks how safe a shingles vaccine (Shingrix, a non-live vaccine) is for adults with lupus. You might be invited if you have lupus and haven’t had certain shingles or chickenpox-related vaccines recently, and if your lupus symptoms and immune health meet the study rules.
New York, New YorkAges 18–90 - NCT05680480RecruitingPhase 2
Telitacicept for active lupus kidney inflammation
This trial tests telitacicept to improve lupus nephritis (inflammation of the kidneys caused by lupus). It targets people with active kidney disease confirmed by biopsy and compares outcomes while you receive standard steroid plus mycophenolate treatment.
Hefei, AnhuiAges 18–75
Hear when a new Lupus or SLE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus or sle?
- Yes. Clin2 currently lists 344 recruiting lupus or sle studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus or sle trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus or sle trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.